Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. - Wikidata - awgldk - TriplyDB

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

http://www.wikidata.org/entity/Q53907769

about

Natriuretic peptides for acute heart failure Natriuretic peptides for acute heart failure Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events Management of Patients Admitted with Acute Decompensated Heart Failure Natriuretic Peptides and Cardiometabolic Health Cardiovascular and renal effects of carperitide and nesiritide in cardiovascular surgery patients: a systematic review and meta-analysis Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics Phosphodiesterases and cardiac cGMP: evolving roles and controversies Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials Diagnosing and managing acute heart failure in the emergency department Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo Potential new drug treatments for congestive heart failure.BNP and Heart Failure: Preclinical and Clinical Trial Data.Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation.Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study.Heart failure in the elderly.Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent Innovative Therapeutics: Designer Natriuretic Peptides.Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.Nesiritide in acute decompensated heart failure: current status and future perspectives Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt.A retrospective characterization of worsening renal function in patients with acute decompensated heart failure receiving nesiritide.Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities.An update on nesiritide for treatment of decompensated heart failure.B-type natriuretic peptide: the level and the drug--partners in the diagnosis of congestive heart failure.Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide.The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure.Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects.A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.Natriuretic peptides and salt sensitivity: endocrine cardiorenal integration in heart failure.Present and future pharmacotherapy for heart failure.Current treatment options for early management in acute decompensated heart failure.Acute renal failure in hospitalized patients: part II.Heart failure in 10 years time: focus on pharmacological treatment.Nesiritide: a new drug for the treatment of decompensated heart failure.Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model "BNP" for heart failure: role of nesiritide in cardiovascular therapeutics.

P2860

Q24194433-C9F54F13-FE2F-4EDE-8210-28A969A49603 Q24245105-7584A0FE-5C51-4367-9B7E-C94C3F056FDA Q26778333-7329E911-BF51-4C76-A5E2-4886DF0D2EB9 Q26786085-795B077B-325B-4479-8ED8-BA10AC8DD966 Q26827702-BC4EF131-DC6E-4062-B94A-BA7E52680611 Q26851289-AC6EF0AE-9DD7-4F9B-94F5-918E14B96219 Q27004000-B9CBCE41-0648-4456-B1A2-8F43F744642E Q27692588-74297BEA-E242-4B39-8011-71E02B2EE185 Q28078389-953EBEDC-0C9B-4051-960F-99D787228199 Q28080130-2F63E789-A548-4946-BD92-33C1383F6FD1 Q28085736-6576792B-36C2-4F3C-BF93-143F058BBC5A Q28088583-9C5AC5DB-97EB-498A-886B-A27C2FD5EE09 Q28511213-317237EF-E5CF-4E66-A8FA-84C30C3EFA0E Q30251531-CAAFCA42-DBB6-4CCC-80A8-B688A9DF8A27 Q30909922-F5E17718-CC63-4D69-8CE5-68701A1AE460 Q31816687-E6543C5D-C5BB-44A9-82D2-9F579AC2F1D9 Q33186937-5D380C41-17AF-4313-B918-5DB89034D175 Q33196161-079E3BA2-F061-4456-B5EE-D48BB329A63C Q33573360-2CB90229-AEA8-4F8E-B116-844E863089E7 Q33653332-AC492589-EC2B-48EE-92F8-34B083741887 Q33735342-11A2A169-36AD-4516-A022-64FF3947FFB3 Q33878162-6C7EFAD4-602B-4882-A642-67BE166C9B63 Q34048466-A389105B-735B-46F2-A21C-13DC1C40BACD Q34069726-78E37196-6B96-4E81-9946-AE571E395C44 Q34161199-3F881B61-1C3C-4A28-A988-D729A59E92E0 Q34193579-B4691F38-D16C-43BE-A85E-470EA7B46F69 Q34232053-644D0366-CC3C-4706-B374-45A1D23615AF Q34297057-642AAE55-AFBD-42E6-85F9-F7330521BB16 Q34304189-035F527F-C26E-4E7B-B8F3-793C9CA16A6B Q34346282-129C2F6C-B86D-45C4-A37E-FDDF1B6BF531 Q34421211-86073146-2CA0-4052-BF6B-154727547A39 Q34496097-B74AF9DF-67E2-45A5-B162-D8841C1F777C Q34513194-E983864F-062F-4BDF-AB28-F0D0A9A45F45 Q34706912-D2F72A6F-137C-4513-BE4D-8415B1BAB062 Q34796529-87FCF911-7630-475D-B9A3-297DDB8B0F31 Q34797006-AC52AE51-3BAB-451A-8559-9E061DA495C4 Q34817094-9BE677B4-58E3-49CD-9F83-0C89E6719CAC Q34859064-64BE77B2-D3B5-40FA-9BBA-76D47FEAD77C Q34891600-FE8A21D6-924B-4230-97B1-B33C83D6D473 Q34943458-E2403C66-3C5F-4047-B008-4750D2F4F527

P2860

Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

http://www.wikidata.org/entity/Q53907769

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh

2000年學術文章

@zh-hant

name

Intravenous nesiritide, a natr ...... ilure. Nesiritide Study Group.

@en

Intravenous nesiritide, a natr ...... ilure. Nesiritide Study Group.

@nl

type

label

Intravenous nesiritide, a natr ...... ilure. Nesiritide Study Group.

@en

Intravenous nesiritide, a natr ...... ilure. Nesiritide Study Group.

@nl

prefLabel

Intravenous nesiritide, a natr ...... ilure. Nesiritide Study Group.

@en

Intravenous nesiritide, a natr ...... ilure. Nesiritide Study Group.

@nl

P1433

Q53907769-5E1B8288-C4E8-43FF-8A5E-D744ACB55BCA

P1476

Q53907769-61533D37-98FD-430A-9E38-FBCD9C4975BA

P2093

Q53907769-1389FD6E-36DB-44FE-AF9D-D204D69687AA

Q53907769-1A679331-209D-4F31-A8CE-2207EA74C983

Q53907769-650D6EDA-B2CF-4410-B2B3-331827D9A8B1

Q53907769-75B997C8-E4E7-4B77-B6E7-B03582AD3A10

Q53907769-94068759-463A-4223-94E3-BBCB71C59507

Q53907769-B6434017-2EFD-41C3-BC57-18D73C5621F5

Q53907769-BEC10743-855C-448C-A923-83C4D447B3F8

Q53907769-CA689EBC-7A13-46AB-B2FF-A522A5B5A98E

Q53907769-D79F4178-A8A9-49B8-8473-13FAA29DA985

Q53907769-D889A4C6-BDCD-4C09-A7BC-4FE1C9162059

P304

Q53907769-A6546C3A-1248-4049-8B1B-F75D5A7E4598

P31

Q53907769-6F7942B1-2CA1-40B9-8080-B3DA3A24C011

P356

Q53907769-1A8BFE46-A20C-40A4-AD44-A3448EFED427

P407

Q53907769-F106F722-4AF0-4F70-814F-A4B444234BD0

P433

Q53907769-67C0A9BC-385A-4CA2-AEFF-1B1A1448012F

P478

Q53907769-F7E90625-C758-46FC-AAAF-9B7EDB4EFEB3

P577

Q53907769-8997C326-A479-49D6-8AED-2AB4C833E1F9

P5875

Q53907769-3AEC5C2C-8793-439B-854C-CFD81D72A54C

P698

Q53907769-AF771956-A9FC-4A95-A2ED-9C2CC607BF35

P921

Q53907769-F3DF8C41-64C4-421E-B1C5-C32C89173864

P356

NEJM200007273430403

P1433

The New England Journal of Medicine

P1476

Intravenous nesiritide, a natr ...... ilure. Nesiritide Study Group.

@en

P2093

Abraham WT

http://www.w3.org/2001/XMLSchema#string

Bourge RC

http://www.w3.org/2001/XMLSchema#string

Colucci WS

http://www.w3.org/2001/XMLSchema#string

Elkayam U

http://www.w3.org/2001/XMLSchema#string

Givertz MM

http://www.w3.org/2001/XMLSchema#string

Haught WH

http://www.w3.org/2001/XMLSchema#string

Horton DP

http://www.w3.org/2001/XMLSchema#string

Johnson AD

http://www.w3.org/2001/XMLSchema#string

LeJemtel TH

http://www.w3.org/2001/XMLSchema#string

Liang CS

http://www.w3.org/2001/XMLSchema#string

P304

246-253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJM200007273430403

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

343

http://www.w3.org/2001/XMLSchema#string

P577

2000-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

246000449

http://www.w3.org/2001/XMLSchema#string

P698

10911006

http://www.w3.org/2001/XMLSchema#string

P921